PLD1

Across TCGA pan-cancer cohorts, PLD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLD1 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLD1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PLD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.771	0.524	.001	32	view →
LUAD	OS	Median	II,III,IV	0.429	0.911	.008	7	view →
CCRCC	DFS	Quartile	II,III,IV	0.201	1.000	.024	6	view →
LSCC	DFS	Tertile	All	0.535	1.000	.013	5	view →
PDAC	OS	Median	III,IV	0.548	0.194	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLD1–HNSC (DFS)

Open the HNSC breakdown →